List of Excipients in Branded Drug VYVGART HYTRULO

« Back to Dashboard

VYVGART HYTRULO Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 9, 2026

VYVGART HYTRULO combines efgartigimod alfa, an FcRn antagonist, with recombinant human hyaluronidase PH20. Its excipient strategy is primarily a delivery strategy: hyaluronidase enables subcutaneous administration of a high-dose biologic, while histidine, arginine, polysorbate 80, and related formulation components support protein stability, solubility, and manufacturability. The commercial opportunity is the conversion of intravenous VYVGART patients to a shorter subcutaneous administration route, supported by differentiated formulation, device, supply-chain, and biosimilar barriers.

What is VYVGART HYTRULO and how is it administered?

VYVGART HYTRULO is a ready-to-use subcutaneous formulation approved by the FDA on June 20, 2023, for adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive or anti-muscle-specific tyrosine kinase antibody positive. The product is marketed by argenx under biologics license application 761309. [1]

Each vial contains:

Component	Amount per vial	Commercial role
Efgartigimod alfa	1,000 mg	FcRn antagonist and active biologic
Recombinant human hyaluronidase PH20	20,000 units	Enables subcutaneous dispersion of the large-volume biologic dose
Histidine and histidine hydrochloride	Formulation buffer system	pH control and protein stability
Arginine hydrochloride	Protein-solubility excipient	Reduces aggregation and supports high-concentration formulation
Polysorbate 80	Surfactant	Limits interfacial adsorption and agitation-related aggregation
Water for injection	q.s.	Vehicle

The labeled administration volume is 5.6 mL, with 1.25 mL administered subcutaneously over approximately 30 to 90 seconds by a healthcare professional. The full vial is not injected as a single 5.6 mL bolus. [1]

The formulation supports four weekly administrations in an initial treatment cycle. Subsequent cycles are administered according to clinical response and physician assessment. VYVGART HYTRULO is therefore a chronic, repeat-use product rather than a one-time biologic intervention.

Why is hyaluronidase the central excipient strategy?

Hyaluronidase is the key enabling component in the product. It temporarily degrades hyaluronan in the extracellular matrix at the injection site, increasing local tissue permeability and allowing dispersion of a dose that would otherwise be difficult to deliver subcutaneously.

For VYVGART HYTRULO, recombinant human hyaluronidase PH20 does more than improve injection comfort. It changes the commercial route of administration from intravenous infusion to a short subcutaneous injection. The resulting value proposition includes:

• lower infusion-chair utilization;
• shorter administration time;
• reduced need for intravenous access;
• improved clinic throughput;
• potential for broader use in outpatient neurology practices;
• a product-level distinction from intravenous efgartigimod.

The hyaluronidase component also creates technical and regulatory complexity. A follow-on product must match or adequately characterize both the efgartigimod component and the hyaluronidase activity, purity, glycosylation profile, potency, impurities, and interaction profile.

How does VYVGART HYTRULO compare with intravenous VYVGART?

Attribute	VYVGART	VYVGART HYTRULO
Active biologic	Efgartigimod alfa-fcab	Efgartigimod alfa
Route	Intravenous infusion	Subcutaneous injection
Administration burden	Infusion-center visit	Short healthcare-professional injection
Enabling technology	Intravenous delivery	Recombinant human hyaluronidase PH20
Commercial purpose	Original route	Route-of-administration expansion
Main switching opportunity	Existing IV patients	Conversion from IV to SC
Key formulation risk	Protein stability during infusion preparation	Protein stability plus hyaluronidase compatibility and injection performance

The subcutaneous product is not simply an interchangeable presentation of VYVGART. Its formulation, administration method, clinical development package, manufacturing process, and regulatory description create a separate product position.

What excipients are protected by the VYVGART HYTRULO formulation?

The commercial protection is likely to arise from a combination of formulation claims, combination-product claims, manufacturing claims, and method-of-use claims rather than from ownership of common excipients individually.

Histidine and histidine hydrochloride

The histidine system provides pH control in a range compatible with efgartigimod stability and injection tolerability. Histidine buffers are common in monoclonal-antibody and Fc-fusion formulations, so the commercial strength of claims directed only to histidine is generally weaker than claims that specify:

• defined pH and concentration ranges;
• a particular efgartigimod concentration;
• compatibility with recombinant hyaluronidase;
• limits on aggregation or particulates;
• long-term refrigerated stability;
• a specific administration volume or injection profile.

Arginine hydrochloride

Arginine hydrochloride is used as a solubility and aggregation-control excipient. High-dose biologics can face viscosity, self-association, and particle-formation problems. Arginine can improve solution behavior, but it can also affect osmolality, injection tolerability, and protein conformation.

The strongest commercial formulation claims would typically link arginine concentration to measurable product attributes, such as:

• reduced high-molecular-weight species;
• reduced subvisible particles;
• acceptable viscosity;
• retained FcRn-binding activity;
• retained hyaluronidase activity;
• stability under shipping and handling stress.

Polysorbate 80

Polysorbate 80 protects the biologic against adsorption to vial, syringe, and tubing surfaces. It is also associated with known quality risks, including oxidation, hydrolysis, peroxide formation, and particle generation. These risks are relevant because degradation products can affect protein stability and immunogenicity.

A supplier or competitor seeking commercial opportunity could focus on:

• low-peroxide polysorbate 80;
• tightly controlled fatty-acid composition;
• improved oxidation resistance;
• analytical methods for polysorbate degradation;
• packaging systems that reduce surfactant interaction;
• alternative surfactants with equivalent biological performance.

A replacement excipient would face a high regulatory burden. Any substitution would require comparability data covering potency, aggregation, particles, stability, extractables, and immunogenicity-related quality attributes.

Recombinant human hyaluronidase PH20

Hyaluronidase has the highest strategic value in the excipient system. It is a recombinant enzyme with its own production process, potency assay, impurity profile, and supply requirements. The key attributes include:

• enzymatic activity at the injection site;
• purity and host-cell-protein control;
• glycosylation and charge profile;
• compatibility with efgartigimod;
• retained activity during storage;
• low endotoxin and bioburden;
• absence of unacceptable degradation products.

Hyaluronidase supply is a potential manufacturing bottleneck. A second source would need to demonstrate functional equivalence, process consistency, viral safety, and compatibility with the efgartigimod drug product.

What patents protect VYVGART HYTRULO?

VYVGART HYTRULO is protected through the combined estate around efgartigimod, FcRn antagonism, subcutaneous delivery, hyaluronidase-enabled administration, formulations, dosing, and manufacturing. The biologic itself is not listed in the FDA Orange Book because the Orange Book primarily covers small-molecule drug products approved through NDAs and related applications. Biologic patent and exclusivity information is evaluated through the Purple Book and patent records. [2]

The relevant protection categories are:

Protection category	Potential subject matter	Business effect
Active biologic composition	Efgartigimod sequence, Fc modification, or antibody-fragment structure	Blocks products using the same or substantially similar biologic
FcRn method of treatment	Dosing patients with autoimmune disease	Limits competing clinical uses
Subcutaneous administration	Delivery of efgartigimod with hyaluronidase	Protects the commercial route conversion
Formulation	Buffer, amino acid, surfactant, concentration, and stability ranges	Raises formulation-design-around costs
Combination product	Efgartigimod plus recombinant hyaluronidase	Requires a competitor to address both components
Manufacturing	Cell culture, purification, conjugation or mixing, and fill-finish processes	Can restrict process alternatives
Device or container closure	Vial, syringe, injection system, or administration configuration	Adds product-level barriers

The most valuable claims are likely to be those that connect the formulation to the subcutaneous administration method. A patent covering a generic histidine-polysorbate formulation is less commercially defensible than a claim requiring a defined efgartigimod concentration, hyaluronidase activity, injection volume, and stability profile.

Exact patent enforceability depends on claim scope, prosecution history, terminal disclaimers, maintenance fees, post-grant proceedings, and jurisdiction. A patent family may have different expiration dates across the United States, Europe, Japan, and other markets.

When does VYVGART HYTRULO lose exclusivity?

VYVGART HYTRULO has several exclusivity layers rather than one single loss-of-exclusivity date.

FDA regulatory exclusivity

As a biologic, the reference-product framework generally provides 12 years of reference-product exclusivity from the first licensure date of the relevant reference product under the Biologics Price Competition and Innovation Act. FDA approval of VYVGART HYTRULO occurred in 2023, but the statutory analysis must distinguish the original efgartigimod product from the later subcutaneous presentation. [3]

The original VYVGART intravenous product was approved in December 2021. The subcutaneous product may not receive a completely independent 12-year reference-product period simply because it uses a new route and formulation. The applicable exclusivity position depends on how FDA applies first licensure rules to the product and its active moiety.

Patent exclusivity

Patent expiry can extend beyond, or fall before, statutory biologic exclusivity. Relevant patents may cover:

• efgartigimod;
• FcRn antagonism;
• treatment of generalized myasthenia gravis;
• subcutaneous delivery;
• hyaluronidase combinations;
• pharmaceutical compositions;
• manufacturing processes.

A biosimilar applicant may challenge patents before commercial launch through the BPCIA patent-exchange process. A patent expiration date alone does not establish launch freedom because other unexpired claims may remain relevant.

Orphan-drug exclusivity

Generalized myasthenia gravis is an orphan indication. Orphan exclusivity generally lasts seven years from approval for the same drug and indication, subject to statutory exceptions. The interaction between orphan exclusivity for the original VYVGART approval and the later HYTRULO presentation must be assessed on the specific product and indication. [4]

What generic and biosimilar entry risks exist for VYVGART HYTRULO?

The principal competitive threat is biosimilar or interchangeable-biologic entry, not traditional generic entry. A biosimilar applicant would face several layers of work:

1. analytical similarity for efgartigimod;
2. comparative characterization of hyaluronidase;
3. formulation and excipient comparability;
4. subcutaneous injection performance;
5. immunogenicity assessment;
6. device or container-closure compatibility;
7. patent litigation under the BPCIA;
8. commercial-scale manufacturing validation.

A competing product could pursue several strategies:

Entry strategy	Advantages	Main barrier
IV efgartigimod biosimilar	Avoids hyaluronidase manufacturing	Competes primarily with VYVGART, not HYTRULO
SC efgartigimod with hyaluronidase	Matches the leading convenience proposition	Requires dual-component comparability
SC efgartigimod without hyaluronidase	Potentially avoids PH20 supply dependence	May require a different concentration, device, or dosing volume
New FcRn antagonist	Avoids direct biosimilar pathway	Requires a new clinical and commercial program
Oral or long-acting FcRn alternative	Differentiates route or frequency	Higher development risk and potentially different efficacy profile

The most credible near-term threat is a biosimilar or follow-on biologic that matches the subcutaneous convenience profile while competing on price and payer access.

Which commercial opportunities exist for excipient suppliers and manufacturers?

Hyaluronidase supply and second sourcing

The most valuable excipient opportunity is qualified recombinant human hyaluronidase. Suppliers can compete on:

• capacity;
• batch consistency;
• enzyme activity;
• low impurity burden;
• validated cold-chain stability;
• technical-transfer support;
• regulatory documentation;
• dual-site manufacturing.

A second source could improve supply resilience for argenx or support a follow-on product. The qualification cycle would be long because the enzyme is functionally linked to delivery performance.

Polysorbate 80 and surfactant alternatives

Specialty excipient suppliers can offer pharmaceutical-grade polysorbate 80 with:

• low peroxide levels;
• controlled hydrolysis;
• defined impurity specifications;
• improved container compatibility;
• lot-release testing tailored to biologics.

Alternative surfactants may have commercial potential, but switching would require extensive comparability work. The business case is strongest where polysorbate degradation limits shelf life or creates particulate risk.

Fill-finish and combination-product manufacturing

VYVGART HYTRULO is well suited to contract development and manufacturing organizations with capabilities in:

• aseptic vial filling;
• biologic drug-product manufacturing;
• enzyme-containing formulations;
• low-volume subcutaneous injection systems;
• extractables and leachables testing;
• refrigerated distribution;
• stability programs under ICH Q5C conditions. [5]

The manufacturing process must preserve both efgartigimod potency and hyaluronidase activity. Mixing order, hold time, shear, filtration, temperature exposure, and vial adsorption can affect the final product.

Device and administration systems

The label requires administration by a healthcare professional, leaving room for future delivery innovation. Potential opportunities include:

• prefilled syringes;
• autoinjectors;
• on-body injectors;
• dose-volume reduction;
• higher-concentration formulations;
• clinic workflow systems;
• home-administration models if supported by future labeling.

A device change can create new intellectual-property value, but it also introduces human-factors, container-closure, dose-accuracy, and combination-product requirements.

How strong is the VYVGART HYTRULO patent estate?

The estate is commercially stronger than a conventional excipient patent position because it can combine biologic composition claims with route-of-administration and combination claims. Its strongest defensive features are:

• the complexity of reproducing a biologic FcRn antagonist;
• the need to match a hyaluronidase-enabled subcutaneous route;
• potential formulation and manufacturing claims;
• the clinical value of converting patients from intravenous therapy;
• the difficulty of designing around both active biologic and delivery technology.

Its weaker points are common-excipient vulnerability and possible design-around strategies. Histidine, arginine hydrochloride, polysorbate 80, and water for injection are widely used materials. A competitor could attempt to retain the active biologic while modifying buffer composition, surfactant selection, concentration, device, or administration schedule.

Patent strength therefore depends less on the presence of common excipients than on whether issued claims require the specific combination of efgartigimod, hyaluronidase, concentration, injection method, and clinical use.

What is the commercial exposure for argenx?

VYVGART is argenx's core commercial franchise. The company reported approximately $2.7 billion in VYVGART net product sales for 2024, reflecting strong uptake of both intravenous and subcutaneous presentations. [6]

The commercial stakes include:

• preserving the conversion of IV patients to HYTRULO;
• expanding treatment in neurology clinics;
• defending reimbursement against lower-cost FcRn competitors;
• maintaining supply of recombinant hyaluronidase;
• protecting the formulation and delivery platform;
• extending use into additional autoimmune indications.

The principal commercial risk is not limited to biosimilar pricing. Competitors may challenge the franchise with alternative FcRn inhibitors, complement inhibitors, oral immunomodulators, longer-acting biologics, or products that reduce clinic administration burden.

Key Takeaways

• VYVGART HYTRULO uses recombinant human hyaluronidase PH20 as the central delivery-enabling excipient.
• Histidine, arginine hydrochloride, and polysorbate 80 support pH control, solubility, and protein stability.
• The product's commercial value comes from converting intravenous efgartigimod therapy to a short subcutaneous administration.
• Hyaluronidase creates a meaningful technical and supply-chain barrier for biosimilar developers.
• The product is not listed in the Orange Book; biologic exclusivity and patent information are evaluated through the Purple Book, BLA records, and patent filings.
• The strongest protection is likely to come from the combined estate covering efgartigimod, hyaluronidase-enabled delivery, formulation, dosing, and manufacturing.
• Specialty opportunities exist in recombinant hyaluronidase supply, low-peroxide polysorbate 80, biologic fill-finish, device systems, and formulation redesign.
• The principal entry risk is a subcutaneous biosimilar or follow-on biologic that matches HYTRULO's administration convenience.

FAQs

Can VYVGART HYTRULO be administered at home?

The FDA labeling specifies administration by a healthcare professional. A future home-use presentation would require supporting device, human-factors, safety, and regulatory data.

Is hyaluronidase in VYVGART HYTRULO a biologically active ingredient?

Yes. Hyaluronidase is included to increase subcutaneous tissue permeability and enable dispersion of the efgartigimod dose. It has a functional delivery role distinct from conventional inactive excipients.

Could a biosimilar use a different hyaluronidase?

Potentially, but the applicant would need to establish that the alternative enzyme provides comparable delivery performance, quality, safety, and compatibility with efgartigimod. The regulatory pathway would depend on the product's structure and proposed labeling.

Does VYVGART HYTRULO have a separate Orange Book listing?

No. VYVGART HYTRULO is a biologic licensed under a BLA rather than a conventional small-molecule product approved under an NDA. The Purple Book is the relevant FDA biologic reference source.

What is the most attractive excipient business opportunity?

Recombinant human hyaluronidase supply is the highest-value opportunity because it is functionally essential to the subcutaneous product and more specialized than histidine, arginine hydrochloride, or polysorbate 80.

References

1. U.S. Food and Drug Administration. (2023). VYVGART HYTRULO prescribing information. FDA.

2. U.S. Food and Drug Administration. (n.d.). Purple Book: Database of licensed biological products. FDA.

3. Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, §§ 7001-7003, 124 Stat. 119 (2010).

4. U.S. Food and Drug Administration. (2023). Orphan drug designation and exclusivity. FDA.

5. International Council for Harmonisation. (2005). ICH Q5C: Quality of biotechnological products: Stability testing of biotechnological/biological products.

6. argenx SE. (2025). Annual report 2024. argenx SE.